← All trials
NCT06939595
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2025
- Primary completion
- Feb 28, 2027
- Completion date
- Jul 31, 2028
- First posted
- Apr 23, 2025
- Last posted
- Apr 23, 2025
- Enrollment
- 606
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CelltrionLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.